Alembic Pharma

Alembic Pharmaceuticals Limited is the listed pharmaceutical flagship of the Vadodara-based Alembic Group, a vertically integrated developer, manufacturer and marketer of branded formulations for India, generic formulations for regulated and semi-regulated export markets, and active pharmaceutical ingredients (APIs) for captive and third-party use. The company traces its operating heritage to 1907, when Alembic Chemical Works Co. Ltd was founded in Vadodara; the modern listed entity was created by the demerger of Alembic Ltd's pharmaceutical business effective 1 April 2010 and listed in September 2011.

Positioning statement (150 words). Alembic occupies an unusual middle position in Indian pharma: too large to be a niche specialist, too small to compete on scale with the top decile. Its distinctiveness lies in vertical integration — captive API supply feeding a formulation base that now spans oral solids, oncology orals and injectables, general injectables, ophthalmics and dermatology — and in an unusually heavy historical R&D commitment that funded a 274-filing ANDA pipeline. The company is the 21st-ranked player in the Indian Pharmaceutical Market with roughly 1.2% share, but derives about two-thirds of revenue from exports, with the US alone at approximately 30%. After a difficult FY2022–FY2024 stretch in which capacity was commissioned faster than it could be filled, FY2026 marked an inflection: revenue grew 10% to INR 7,345 crore, margins recovered to 15.9%, and the company entered US branded specialty pharmaceuticals with Pivya. The open questions are domestic execution, US price erosion and working-capital discipline.

2.1 What the company does

Alembic Pharmaceuticals develops, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients. The business is conventionally described by management across four commercial engines:

1. India Branded Formulations — prescription-driven branded generics sold to Indian physicians through a field force of over 5,500 medical representatives across 21 marketing divisions, plus an Animal Health division.
2. US Formulations — generic products commercialised in the United States through a wholly owned front-end (Alembic Pharmaceuticals, Inc.), plus, from Q4 FY2026, a branded specialty platform operated through Alembic Therapeutics LLC.
3. Ex-US International Formulations — generic and branded-generic formulations sold in Europe, Canada, Australia, Brazil, Chile, South Africa, the Middle East and other markets, historically largely through partners, increasingly through owned subsidiaries.
4. API — active pharmaceutical ingredients supplied captively for Alembic's own formulations and sold to more than 60 countries; 152 cumulative US Drug Master Files filed as at 30 June 2026.

The company describes itself in filings as a vertically integrated, research-and-development-driven pharmaceutical company engaged in the manufacture and marketing of generic pharmaceutical products globally, with research and manufacturing facilities approved by regulators in developed markets including the USFDA. Its stated mission, reproduced in the Q4 FY26 investor presentation, is to improve healthcare with innovation, commitment and trust.

2.2 Independent characterisation

Three structural observations bear on how the business should be read.

First, this is not a "domestic branded generics" company despite its Indian heritage. In FY2026, domestic branded formulations were roughly 33% of consolidated revenue, international generic formulations roughly 50%, and API roughly 16% (CARE Ratings, 11 June 2026). The economics of the enterprise are therefore driven far more by US and rest-of-world generic pricing than by the Indian prescription market. That is a materially different risk profile from peers such as Mankind or Alkem, and closer to Ajanta or Ipca, though with a larger US weighting than either.

Second, the revenue model is almost entirely product sales. There is no subscription element, negligible disclosed licensing income, and only modest out-licensing and contract-manufacturing activity, which management referenced in the June 2026 CRISIL rationale as an emerging lever for filling under-utilised capacity at F2 and F3. The nearest thing to a services line is the CMO/out-licensing opportunity set, which is not separately disclosed. Alembic Therapeutics' Pivya is licensed-in/acquired rather than internally discovered, and the two complementary women's-health products added in FY2027 were in-licensed — so the "branded specialty" business is a commercialisation model, not a discovery model.

Third, the value-chain position is unusually deep for a company of this size. Alembic makes its own API for key molecules, formulates across five dosage-form platforms, holds its own US front-end and distribution relationships, and now has its own US branded field force. Vertical integration is a genuine differentiator on supply security and cost, but it also means fixed-cost absorption is the single most important swing factor in margins — which is precisely what has constrained profitability since the FY2019–FY2022 capex cycle.

2.3 Customer types and end-markets

10.1 Stated strategic themes

Management's own framing, drawn from the Q1 FY2027 call and Q4 FY26 presentation, rests on five pillars:

1. Complex generics and specialty pipeline. Managing Director Pranav Amin framed the operating environment as one in which "execution quality, portfolio choices, manufacturing capabilities, and launch discipline are increasingly becoming the key differentiators." The company describes itself as "strategically evolving the portfolio and pipeline across complex platforms and specialty segments."
2. US branded platform. Building a scalable US specialty franchise anchored on women's health, with Pivya as the beachhead and additional in-licensed products complementing it.
3. India chronic and prescription quality. Stated priorities are a robust chronic portfolio, high-quality prescriptions, deeper specialty-physician engagement and sharper commercial execution.
4. International market expansion via owned front-ends. Converting the ex-US business from pure partner-led B2B to a mixed model with direct presence.
5. Operating leverage and capital discipline. Debottlenecking, capacity enhancement and better utilisation of newer facilities, with capex held to approximately INR 400 crore annually and funded from internal accruals.

The Q4 FY26 "Value Proposition" slide lists: developing a specialty drug pipeline for India; exploring opportunities in injectables; supplying APIs to 60+ countries; consistent dividend payout; ranking 21st in the Indian formulations market; established presence in Chile and UAE; expanding the product portfolio in the USA; and strengthening presence in Canada, South Africa, LATAM and the Middle East.

10.2 Announced strategic initiatives, last 24 months

10.3 ESG commitments with targets

10.4 Management's medium-term financial targets

An earlier and more ambitious framing — EBITDA margins of 18–20% "over the next couple of years," articulated in November 2025 — has effectively been superseded by the more conservative FY2027 guidance of approximately 16%. Investors should treat the 18–20% aspiration as an FY2028-plus scenario contingent on the branded platform turning profitable.

5.1 India Branded Formulations — commercial architecture

As at 31 March 2026 the India branded business comprised approximately 208 brands, over 1,000 SKUs (CARE Ratings), a field force of 5,500+ medical representatives organised into 21 marketing divisions, reaching approximately 246,000 prescribers and generating 136.5 million prescriptions on a MAT March 2026 basis. By MAT June 2026 the prescription base had risen to 137.6 million. Alembic ranks 21st in the Indian Pharmaceutical Market with approximately 1.2% value share (IQVIA MAT March 2026) and 17th by prescription volume. Approximately 13% of the product portfolio is listed under the NLEM and therefore subject to DPCO price control.

Four flagship brands exceeded INR 100 crore (INR 1 billion) in annual sales in FY2026; by Q1 FY2027 the company reported five such brands. The top ten domestic brands constituted approximately 37% of branded formulation sales in FY2026 (38% in FY2025), and the top five therapies contributed approximately 75% of domestic revenue.

5.2 India Branded — therapy mix

Source: Q4 FY26 Investor Presentation. The Q1 FY2027 deck reports a slightly different mix — anti-infectives 15%, gynaecology 15%, cardiology 14%, gastrology 11%, animal health 22% — reflecting quarterly seasonality.

The specialty/acute/animal-health split moved from 52% / 30% / 18% in Q4 FY2025 to 52% / 26% / 22% in Q4 FY2026 — evidence of the acute portfolio's structural decline and animal health's rise. On the Q1 FY2027 call the CFO stated that specialty is roughly 60% of India revenue and acute roughly 37%.

5.3 India Branded — named brands, rank and market share (MAT March 2026)

Source: Q4 FY26 Investor Presentation, IQVIA MAT March 2026. Ranks are within the respective molecule group, not the total market.

Other significant brands identified in company and third-party product listings, though without disclosed current rank: REKOOL and REKOOL-D (rabeprazole, gastro), RICHAR CR, GLISEN-MF and GLISEN PM (anti-diabetic), ZEET (cough & cold), MAGADOL (pain), LAVETA and LAVETA-M (levocetirizine, anti-allergic), ROSAVE and ROSAVE-F (rosuvastatin, cardiology), PROTINULES and PROTINULES-PL (nutritional), ULGE-RAFT, ULGEL-A, ETERNEX-M and ETERNEX-T, GERIPOD-D, GERIFLO-D, VITARESP FX, CYCLOSET, ENZICTRA, NEW LIVFIT, OVIGYN D3, WIKORYL-AF, HERMIN, VEHYCAL, VOGO, GLZ PLUS, AL5ZYME, TETAN (telmisartan), D-KOOL (rabeprazole) and STROX.

Named marketing divisions include Megacare (established 1987; infection, allergy and pain management; brands Azithral, Laveta, Magadol), Maxis (cough & cold plus antibiotics, GI, anti-diarrhoeal and pain; brands Althrocin, Wikoryl, Brozeet, Zeet) and the legacy Alembic Pharma division (macrolides: Althrocin, Roxid, Cloff). Pricing is standard Indian branded-generic MRP-based pricing, constrained by DPCO ceilings for NLEM-listed molecules; no per-brand pricing is disclosed.

5.4 Animal Health division

Source: Q4 FY26 Investor Presentation (reported in INR million). CAGR FY2022–FY2026: 22%.

The division operates across livestock, poultry and companion animal segments and holds market leadership in haematinics and antibiotics. Flagship brands are Sharkoferrol (haematinic), Moxel, Xceft and Mceft. Brand-tier structure as at Q4 FY2026: six brands above INR 30 crore annual sales, one in the INR 20–30 crore band, six in INR 10–20 crore, and 19 in INR 2–10 crore. Q4 FY2026 product mix: antibiotics 38%, feed supplement 27%, tonics 18%, supportive therapy 10%, antiparasitic 7%. Q1 FY2027 mix as reported: tonics 37%, feed supplements 34%.

5.5 US Generic Formulations

Sources: Q4 FY26 and Q1 FY27 Investor Presentations. As at 30 June 2026 the 244 approvals comprised 224 final and 20 tentative.

Approved ANDA portfolio by dosage form:

Named US products approved or launched in the eighteen months to August 2026, with reference-listed drug and IQVIA-estimated US market size where disclosed by the company:

Sources: company Regulation 30 disclosures and press releases as reported by exchange-filing aggregators. Market sizes are the company's IQVIA-sourced figures for the twelve-month period stated in each release.

Bosutinib deserves specific note. Alembic holds 180-day marketing exclusivity on the 100 mg and 500 mg strengths, confirmed by the Managing Director on the Q1 FY2027 call, with exclusivity running to November 2026. Management characterised the product as low-volume but well-priced, contributed only one month of sales in Q1 FY2027 (launched June 2026), and cautioned that post-exclusivity economics are difficult to forecast given the small volume base.

5.6 US Branded Specialty — Alembic Therapeutics

The branded model carries no manufacturing investment — product is supplied by a contract manufacturer, and the entire incremental cost base is field force, marketing and promotion. Management guides to breakeven "towards the end of FY2027" with positive contribution from FY2028.

5.7 Ex-US International Formulations

Active partnership markets disclosed: Europe, Canada, Australia, Brazil, Chile and South Africa. The company also cites established presence in Chile and the UAE, and expansion focus on Canada, South Africa, Latin America and the Middle East. In May 2025 management set a target of launching more than 40 new products across international markets (EU, Canada, Australia, South Africa) during FY2026. This is predominantly a B2B, partner-supplied business, which management explicitly identifies as the reason for quarter-to-quarter revenue lumpiness.

5.8 API portfolio

API is supplied to more than 60 countries. Six US DMFs were filed in Q4 FY2026 alone and three in Q1 FY2027. The API-III facility at Karakhadi cleared an ANVISA (Brazil) GMP inspection covering 56 APIs in June 2025 and again in May 2026 without observations. Individual API molecules are not disclosed product-by-product in investor materials; the portfolio is described as covering the anti-infective, gynaecology, cardiology, diabetes, dermatology and oncology therapeutic areas that mirror the formulation business.

6.1 Basis of presentation and a necessary caveat

Two EBITDA conventions circulate for this company and they do not agree. Screener/C-MOTS presents "operating profit" as revenue less operating expenses, excluding other income and exceptional items. The company's own investor deck presents "EBITDA" including other income and, for FY2023, adjusted to exclude the Aleor write-off. CARE Ratings presents "PBILDT" on a third, slightly different basis. All three are shown below with the basis stated, because the differences are material (FY2023 ranges from INR 682 crore to INR 779 crore depending on convention).

6.2 Income statement, FY2022–FY2026 (consolidated)

Zeros in the table indicate that the figure is not publicly disclosed or not available on a comparable basis for that year, not a value of nil. Sources: Screener/C-MOTS consolidated data for the full series; Q4 FY26 Investor Presentation for company-basis EBITDA, gross margin and attributable profit; CARE Ratings 11 June 2026 for PBILDT.

Revenue CAGR. FY2022–FY2026: 8.5%. FY2021–FY2026 (five-year): 6.4%. FY2016–FY2026 (ten-year): approximately 9%. Trailing twelve months to June 2026: INR 7,784 crore, up approximately 14% year on year.

Net profit CAGR. FY2022–FY2026: 6.5%. The five-year figure is negative (-9% on a FY2021 base) because FY2021 contained an exceptional COVID-era earnings peak of INR 1,146 crore that has not been repeated.

6.3 Commentary on income-statement trends, inflections and drivers

The FY2021 peak and the FY2022–FY2023 collapse. Net profit of INR 1,146 crore in FY2021 was a genuine outlier, built on pandemic-era demand and favourable US pricing. Profit fell 55% to INR 521 crore in FY2022 and a further 34% to INR 342 crore in FY2023. Three forces compounded: US price erosion as pandemic pricing normalised; R&D spend running at 15.8% and 12.8% of sales in FY2022 and FY2023 respectively; and — most importantly — the commissioning of new oncology, injectable, ophthalmic and dermatology plants whose fixed costs hit the P&L years before their volumes did. Operating margin compressed from 27% in FY2021 to 12% in FY2023.

The FY2024–FY2026 recovery. Three levers reversed the decline. R&D was cut hard, to 7.6% of sales in FY2024 from 12.8% the prior year — a INR 240 crore swing that flatters the FY2024 recovery and should be understood as such. Utilisation of F2 and F3 began to improve. And the ex-US business, growing at 18–24% annually off a small base, added high-quality incremental volume. Operating margin recovered to 15.0% in FY2024 and 15.3% in FY2026, with CRISIL computing 15.9% on its basis.

The FY2026 tax anomaly. Reported effective tax rate for FY2026 was 3% versus 18% in FY2025, driven by a large tax credit in Q4 FY2026 (the March 2026 quarter showed a negative 70% tax rate). This is why Q4 FY2026 net profit rose 29% year on year to INR 202.70 crore while profit before tax fell 38% to INR 119 crore. Any read of FY2026 earnings quality that ignores this is misleading: pre-tax profit for FY2026 was INR 694 crore, down 2% on FY2025's INR 707 crore. Management confirmed on the Q1 FY2027 call that the company has migrated to the new tax regime, with a normalised effective rate of approximately 22%.

The R&D re-acceleration. FY2026 R&D rose 37% to INR 710 crore (9.6% of sales), driven by peptide development, exhibit batches and higher filing activity. Q4 FY2026 alone saw R&D up 39% year on year. This is a deliberate re-investment after the FY2024–FY2025 austerity, and it is the principal reason FY2026 EBITDA margin did not expand more than it did.

Finance costs. Interest expense has risen five-fold from INR 18 crore in FY2022 to INR 94 crore in FY2026, entirely on working capital. This is the clearest financial symptom of the inventory build discussed in section 6.6.

6.4 Balance sheet, FY2022–FY2026 (consolidated)

Zeros denote not publicly disclosed in the sources reviewed. Sources: Screener/C-MOTS consolidated balance sheet; CRISIL Ratings 30 June 2026 for short-term borrowings, lease liabilities and liquid surplus; book value per share for FY2026 per Screener, earlier years computed from equity divided by 19.66 crore shares.

Goodwill and intangibles. Not separately disclosed in the consolidated summary available. Management stated on the Q1 FY2027 call that intangible assets acquired in connection with the US branded business were capitalised in Q4 FY2026 and are being amortised over approximately seven to eight years, and that roughly 70–75% of the year-on-year increase in depreciation in Q1 FY2027 was attributable to that amortisation. The quantum of the intangible is not publicly disclosed; the CFO declined to give the figure on the call.

Working capital. Gross current assets stood at 224 days as at 31 March 2026 versus 222 days a year earlier (CRISIL). Net working capital increased by approximately INR 330 crore during FY2026, primarily on elevated inventory — a deliberate build for planned launches and for stocking key APIs and inputs against geopolitical supply risk.

6.5 Cash flow, FY2022–FY2026 (consolidated)

Sources: Screener/C-MOTS cash flow statement; Q4 FY26 Investor Presentation for capex. Dividend outflow approximated as DPS multiplied by 19.66 crore shares; note that a fiscal year's declared dividend is typically paid in the following fiscal year. Alembic has not undertaken any share buyback in the period reviewed.

The FY2025 cash flow break is the single most important item in this section. Operating cash flow collapsed to INR 88 crore — a CFO/operating-profit conversion of just 16% against a five-year average near 75% — and free cash flow was negative INR 466 crore. This was funded by a INR 745 crore increase in borrowings (financing inflow of INR 444 crore). The cause was a step-change in working capital: inventory days rose from 350 to 466, receivable days from 60 to 77, and the cash conversion cycle from 253 to 363 days. FY2026 saw a partial normalisation of the cash flow statement (CFO INR 783 crore) but not of the underlying working capital, which deteriorated further on a days basis to a 381-day cash conversion cycle. Gross debt rose again to approximately INR 1,600 crore by 30 June 2026 on higher Q1 receivables. The CFO's stated intention is to return at least to March 2026 levels during FY2027 and then reduce further.

6.6 Ratios, FY2022–FY2026

Zeros denote not disclosed or not computable from available sources. ROE, ROA and asset turnover are computed on average balances by the analyst from the balance-sheet series above; other figures are as reported by the stated source.

On ROIC. A clean ROIC is not computable from public disclosure because segment capital employed and the split of "assets not deployed" are undisclosed. An analyst-computed approximation for FY2026 — NOPAT of roughly INR 626 crore (operating profit less depreciation, taxed at a normalised 22%) over average capital employed of roughly INR 6,777 crore — yields approximately 9.2%. The company's own "operating ROCE" of 15% excludes assets not deployed and exceptional items and is therefore not comparable. The gap between the two is itself the story: roughly INR 683 crore of CWIP and a portion of the gross block are not yet earning.

On returns generally. The uncomfortable fact is that ROE has averaged approximately 11% over five years against a cost of equity that any reasonable estimate would place higher, and Screener's three-year ROE is 12.7%. Alembic destroyed returns during the capex build and has not yet re-earned them. FY2026's 12.4% is progress, not vindication.

6.7 Quarterly trajectory, Q1 FY2025 to Q1 FY2027

Source: Screener/C-MOTS consolidated quarterly data. Q4 FY2026's low operating margin and high net profit reflect the exceptional item and the tax credit described in section 6.3.

22.1 Management guidance summary for FY2027

Revenue growth of approximately mid-teens (raised from low double digits on 4 August 2026); US formulations mid-to-high teens; ex-US formulations 15%; API above 10%; India branded approaching market growth in the high single digits; gross margin of 70–75%; EBITDA margin broadly around 16% with core-business margins in the high teens offset by approximately 150 basis points of US branded dilution; approximately 15 further US launches in the remaining nine months and a similar cadence in FY2028; R&D of INR 750–800 crore; capex of approximately INR 400 crore funded internally; and a reduction of gross debt at least back to March 2026 levels.

22.2 Consensus expectations

Consensus of approximately ten analysts points to FY2027 revenue growth of approximately 13.2% and profit growth of approximately 10.3%, with an average twelve-month target of INR 907–1,014. Applying the mid-point of management guidance to FY2026 actuals implies FY2027 revenue of approximately INR 8,300–8,450 crore and, at a 16% EBITDA margin, EBITDA of approximately INR 1,330–1,350 crore.

22.3 Bull case

1. Operating leverage is real and only partly harvested. CRISIL sees margins reaching 16–17% over the medium term purely on better facility utilisation, cost control and launch-led revenue. If F2 and F3 fill through out-licensing and CMO work — a lever management has begun to pull — the incremental contribution margin is very high because the fixed cost is already sunk. On FY2028 revenue of roughly INR 9,500 crore at an 18% margin, EBITDA would be approximately INR 1,710 crore against INR 1,177 crore in FY2026, a 45% increase on 29% revenue growth.

2. The US branded platform flips from a margin drag to a margin source. It currently costs approximately 150 basis points of consolidated EBITDA and carries no manufacturing capital. Management expects breakeven by end-FY2027 and positive contribution from FY2028. A swing from negative to positive on a 150 basis point base is a 300 basis point delta on a business currently earning 16% — arithmetically the single largest identifiable margin lever the company has.

3. The pipeline is denser than the valuation implies. 244 approvals with 20 tentative, sole first-applicant status on two oncology molecules with 180-day exclusivity, shared exclusivity on a USD 10.5 billion reference molecule, and a NATCO-partnered route into a USD 1.4 billion market. At 23.7x trailing earnings and 2.9x book, the market is capitalising the current margin structure, not the optionality.

22.4 Bear case

1. The domestic business is structurally impaired, not cyclically weak. Losing roughly 19 basis points of IPM share in a year when the market grew 12–16% is not a soft patch. The portfolio is anchored in anti-infectives, which grow below market; the mega-brands are mature; and the fix depends on one recently appointed sales leader turning around a 5,500-person field force with 26% attrition. Management's own guidance is merely to "bridge the gap" to high single digits — that is, to stop losing share, not to gain it.

2. FY2027 growth is flattered by items that do not repeat. Bosutinib exclusivity ends in November 2026, and management explicitly warned that post-exclusivity competition on a low-volume, high-price molecule "will be quite drastic." Approximately 10 percentage points of Q1 FY2027 US growth came from rupee depreciation. Strip both out and the underlying US business grew 20–25%, largely on launches that themselves erode. The FY2028 comparison is going to be hard.

3. Cash generation does not support the growth narrative. Over FY2022–FY2026, cumulative free cash flow was approximately INR 721 crore against cumulative net profit of approximately INR 2,732 crore — a 26% conversion. The cash conversion cycle has lengthened from 237 days in FY2023 to 381 days in FY2026. Working capital has consumed the entire benefit of the earnings recovery and been funded with debt. A company that cannot convert profit to cash cannot fund the US manufacturing footprint that the 2028–2029 tariff schedule may eventually require.

22.5 Catalysts and monitorables, next twelve months

22.6 Analyst verdict

Alembic Pharmaceuticals in August 2026 is a company halfway through a genuine operational repair, priced by the market as though the repair may not complete. Both positions are defensible.

The repair is real. FY2026 delivered 10% revenue growth, a 16% EBITDA margin, INR 783 crore of operating cash flow after a disastrous FY2025, and 15 US launches. Q1 FY2027 accelerated to 26% growth and prompted a guidance upgrade. The capex cycle that destroyed returns between FY2022 and FY2024 is complete, capex is capped at INR 400 crore, and the assets are gradually filling. Credit metrics are strong — AA+/Stable, gearing of 0.27x, interest coverage of 12.5x — and there is no equity dilution risk. The pipeline, at 244 approvals with two sole-first-applicant exclusivities pending, is disproportionate to the company's size.

The scepticism is equally well-founded. A 16% EBITDA margin against Ajanta at 26% and Glenmark at 27% is not a rounding error, and neither is a 12% ROE. The domestic business — one-third of revenue and the historic franchise — is losing share in a booming market, and the remedy is a single new sales leader whose effect will not be measurable for two or three quarters. Cash conversion has deteriorated for three consecutive years, and the FY2026 profit figure is materially flattered by a 3% effective tax rate that has already normalised to 22%. Pre-tax profit actually declined in FY2026.

Two facts should dominate the twelve-month view. First, the arithmetic of the US branded platform is unusually clean: it costs 150 basis points today and management expects it to contribute from FY2028. Nothing else on the P&L offers that magnitude of swing on a capital base of essentially zero. Second, the tariff schedule announced on 22 July 2026 puts a date certain — August 2028 — on a strategic decision that approximately 30% of revenue depends upon, and Alembic has said nothing publicly about how it will respond.

At 23.7x trailing earnings, 2.9x book and roughly 15x EV/EBITDA, the shares embed the current margin structure and little of the recovery. That is a reasonable price for an execution story that has disappointed for five years. It is not a bargain, and it will not become one until either the India business stops bleeding share or the cash conversion cycle comes back inside 300 days. Watch the working capital first; margins will follow.

--